AbbVie (ABBV)

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.

These companies provide growing cash flows.

Eli Lilly is rapidly encroaching on Novo Nordisk's yearslong lead in GLP-1 drugs. Can Novo hold its tentpole position?

AbbVie shares new data for Temab-A, ABBV-706, and PVEK across lung, colorectal, and blood cancers ahead of the ASCO oncology conference.

There's little doubt these pharmaceutical companies' costs will soon be rising at least a little.

Here are three dividend-paying stocks that warrant closer examination.

Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 6.7%. This performance was disappointing since the S&P 500 held its ground.

For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.

Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.

Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session.

FDA grants accelerated approval to AbbVie's Emrelis for c-Met overexpressing NSCLC; siRNA partnership with ADARx includes $335 million upfront.